Using probiotics to improve cognitive function in mild Alzheimer's Disease
Effect of Probiotics on Cognitive Functioning of Patients With Mild Alzheimer's Disease
This study is testing if taking probiotics can help improve thinking skills and reduce inflammation in people with mild Alzheimer's Disease.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 65 Years to 85 Years |
| Sex | All |
| Sponsor | University of Nicosia Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Nicosia) |
| Trial ID | NCT06181513 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of probiotics on patients with mild Alzheimer's Disease by comparing cognitive function and neuroinflammation levels between those receiving probiotics and a placebo group. Participants will undergo neuropsychological testing, blood tests for inflammatory markers, and assessments of their microbiome composition and dietary habits. The goal is to determine if probiotics can enhance cognitive performance and modify neurophysiological measures in this population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 65 and older with mild Alzheimer's Disease, as indicated by specific cognitive test scores.
Not a fit: Patients with other neurological or psychiatric disorders, gastrointestinal issues, or those who have recently used antibiotics or probiotics may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to new dietary interventions that improve cognitive function in patients with mild Alzheimer's Disease.
How similar studies have performed: While the use of probiotics in cognitive disorders is an emerging field, this specific approach in mild Alzheimer's Disease is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥65 years, able to give consent * Mini-Mental State Examination (MMSE) scores 19-23 (mild AD) * approximately equal male:female ratio Exclusion Criteria: * Inability to give consent * other neurological disease * relevant psychiatric disorders (e.g. major depression) * gastrointestinal/metabolic conditions * history of alcohol/substance dependence * use of systemic antibiotics in the previous 6 months * corticosteroid use * immune stimulating medications * immunosuppressive agents * probiotics consumption in the previous 6 months. * immunosuppression * structural heart disease * neutropenia * radiation * active intestinal disease
Where this trial is running
Nicosia
- The Cyprus Institute of Neurology and Genetics — Nicosia, Cyprus (Recruiting)
Study contacts
- Study coordinator: Nicoletta Nicolaou
- Email: nicolaou.nic@unic.ac.cy
- Phone: +35722471903
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.